These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 34257484)

  • 1. 2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.
    Hung CL; Wu YW; Lin CC; Lai CH; Jyh-Ming Juang J; Chao TH; Kuo L; Sung KT; Wang CY; Wang CL; Chu CY; Yu WC; Hou CJ
    Acta Cardiol Sin; 2021 Jul; 37(4):337-354. PubMed ID: 34257484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2024 Update of the TSOC Expert Consensus of Fabry Disease.
    Hung CL; Wu YW; Kuo L; Sung KT; Lin HH; Chang WT; Chang CH; Lai CH; Huang CY; Wang CL; Lin CC; Juang JJ; Chen PS; Wang CY; Chang HC; Chu CY; Wang WH; Tseng H; Kao YT; Wang TD; Yu WC; Chen WJ
    Acta Cardiol Sin; 2024 Sep; 40(5):544-568. PubMed ID: 39308653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.
    Linhart A; Paleček T
    Cardiovasc Diagn Ther; 2021 Apr; 11(2):650-660. PubMed ID: 33968642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An expert consensus document on the management of cardiovascular manifestations of Fabry disease.
    Linhart A; Germain DP; Olivotto I; Akhtar MM; Anastasakis A; Hughes D; Namdar M; Pieroni M; Hagège A; Cecchi F; Gimeno JR; Limongelli G; Elliott P
    Eur J Heart Fail; 2020 Jul; 22(7):1076-1096. PubMed ID: 32640076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
    Liu HC; Lin HY; Yang CF; Liao HC; Hsu TR; Lo CW; Chang FP; Huang CK; Lu YH; Lin SP; Yu WC; Niu DM
    Orphanet J Rare Dis; 2014 Jul; 9():111. PubMed ID: 25047006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac magnetic resonance in Fabry disease.
    Lanzillo C; Fedele E; Martino A; Ferrazza A; Fusco A; Silvetti E; Canestrelli S; Romeo F; Canali E; De Luca L; Golia P; Crescenzi C; Stefanini M; Calò L
    Eur Heart J Suppl; 2023 May; 25(Suppl C):C200-C204. PubMed ID: 37125302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Globotriaosylsphingosine (Lyso-Gb
    Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
    J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.
    Hsu TR; Hung SC; Chang FP; Yu WC; Sung SH; Hsu CL; Dzhagalov I; Yang CF; Chu TH; Lee HJ; Lu YH; Chang SK; Liao HC; Lin HY; Liao TC; Lee PC; Li HY; Yang AH; Ho HC; Chiang CC; Lin CY; Desnick RJ; Niu DM
    J Am Coll Cardiol; 2016 Dec; 68(23):2554-2563. PubMed ID: 27931613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease.
    Taguchi A; Ishii S; Mikame M; Maruyama H
    Mol Genet Metab Rep; 2023 Mar; 34():100952. PubMed ID: 36624895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and Management of Fabry Disease in High-Risk Renal Disease Patients in Taiwan: A Single Center Study.
    Shih CY; You ZH; Tsai SF; Wu MJ; Yu TM; Chuang YW; Chen CH
    Transplant Proc; 2023 May; 55(4):788-791. PubMed ID: 37230899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease: Definition, Incidence, Clinical presentations and Treatment
    Saeed S; Imazio M
    Pak J Med Sci; 2022; 38(8):2337-2344. PubMed ID: 36415271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
    Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry Cardiomyopathy: Current Practice and Future Directions.
    Yim J; Yau O; Yeung DF; Tsang TSM
    Cells; 2021 Jun; 10(6):. PubMed ID: 34204530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry Disease: The Current Treatment Landscape.
    Lenders M; Brand E
    Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Screening of Patients with Fabry Disease.
    Vardarli I; Rischpler C; Herrmann K; Weidemann F
    Ther Clin Risk Manag; 2020; 16():551-558. PubMed ID: 32606714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Lyso-Gb3 Suggests the R118C GLA Mutation Is a Pathological Fabry Variant.
    Talbot A; Nicholls K
    JIMD Rep; 2019; 45():95-98. PubMed ID: 30569317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.
    Auray-Blais C; Lavoie P; Boutin M; Ntwari A; Hsu TR; Huang CK; Niu DM
    Clin Chim Acta; 2017 Mar; 466():185-193. PubMed ID: 28108302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week.
    Pieroni M; Moon JC; Arbustini E; Barriales-Villa R; Camporeale A; Vujkovac AC; Elliott PM; Hagege A; Kuusisto J; Linhart A; Nordbeck P; Olivotto I; Pietilä-Effati P; Namdar M
    J Am Coll Cardiol; 2021 Feb; 77(7):922-936. PubMed ID: 33602475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.
    Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.